Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXCALIBUR3: Resection vs 2nd Line Chemotherapy for Colorectal Liver Metastases
NCT04840186Phase 2Suspended
- Sponsor
- Oslo University Hospital
- Start
- Mar 2021
- Primary completion
- Dec 2024
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in colorectal cancer (CRC) and liver metastases (2 arms), sponsored by Oslo University Hospital. Primary endpoint: Overall Survival at 2 years. Started Mar 2021; status: suspended.
02
Conditions
colorectal cancer (CRC)liver metastases
Beyond the preview
Go deeper on NCT04840186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04840186.